Clinical trial
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in…
NCT00413192 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00413192 |
|---|---|
| Title | E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma |
| Official title | Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Soft Tissue Sarcoma |
| Intervention type | Drug |
| Interventions | E7389 |
| Enrollment | 128 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2012 |
| Completion | Feb 1, 2013 |
| First posted | Dec 19, 2006 |
| Last update posted | Apr 26, 2017 |
| Countries | Belgium, Denmark, France, Germany, Poland |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: